



vTv Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference

September 23, 2015

HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 23, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Stephen Holcombe, President and CEO, and Aaron Burstein, SVP, Clinical Development, will be presenting a corporate overview at the Ladenburg Thalmann 2015 Healthcare Conference. The presentation will take place at 2:30 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City.

A live webcast of the presentation can be accessed on the [News & Events](#) section of the website. The webcast will be archived for 30 days following the presentation on the company website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20150923005380/en/>

Source: vTv Therapeutics Inc.

vTv Therapeutics Inc.

Investors

The Trout Group

Marc Panoff, 646-378-2958

mpanoff@troutgroup.com

or

Media

BMC Communications

Brad Miles, 646-513-3125

bmiles@bmccommunications.com